Bradley W. Lash, MD

Care Provider Overall: 
5
Patient Ratings: 
256
  • Clinical Details
  • Education
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Corning Hospital
  • Guthrie Robert Packer Hospital
Clinical Interests: 
  • Gastroenterology cancer
  • Head & Neck Cancer
  • Lung Cancer
  • Malignant and nonmalignant hematology
  • Melanoma

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of Recommending Care Provider: 
5
Patients' Confidence in Care Provider: 
5
Time Care Provider Spent with Patient: 
5
Care Provider Spoke Using Clear Language: 
5
Care Provider Efforts to Include in Decisions: 
5
Care Provider's Concern for Questions and Worries: 
5
Care Provider's Explanations of Condition/Problem: 
5
Care Provider Information About Medications: 
5
Care Provider Instructions for Follow-Up Care: 
5
Care Provider's Friendliness and Courtesy: 
5
Residency: 
  • Robert Packer Hospital, Sayre, Pa. (Internal Medicine)
Certification: 
  • American Board of Internal Medicine
  • American Board of Internal Medicine/Medical Oncology
  • American Board of Internal Medicine/Hematology
Education: 
  • SUNY Upstate Medical University, College of Medicine, Syracuse, N.Y.
Fellowship: 
  • The Lankenau Medical Center, Wynnewood, Pa. (Hematology/Medical Oncology)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Mirati
Details (Identifier #): NCT02219711
Title: Mirati Therapeutics Inc., 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Mirati
Details (Identifier #): NCT02544633
Title: Mirati 265-109 Amethyst, A Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lash MD, Bradley
Sponsor: MacroGenics
Details (Identifier #): NCT02492711
Title: MacroGenics SOPHIA, CP-MGAH22-04, A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: NSABP Foundation
Details (Identifier #): NCT02664077
Title: NSABP C-13, A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Details (Identifier #): NCT02642042
Title: S1507, A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Details (Identifier #): NCT02154490
Title: S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02585713
Title: RU221501I, A Phase III, Randomized, Open label Study Evaluating the Safety of Apixaban in Subjects with Cancer Related Venous Thromboembolism (BMS# CV185-444)
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Details (Identifier #): NCT01013649
Title: RTOG0848, A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Department: Oncology
Diagnosis: Miscellaneous
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: Internal
Details (Identifier #): NCT02977611
Title: The Safety of a High-Dose, Rapid Infusion of Iron Sucrose in a Non-Dialysis Dependent Population
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02823574
Title: BMS CA209-714,A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN) (CheckMate 714: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 714)
Department: Oncology
Diagnosis: Hematology- Multiple Myeloma
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02726581
Title: BMS CA209-602, A Phase 2/3 Trial Combining Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02538666
Title: CA209-451-0002, A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02477826
Title: CA209227: An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: Roche
Details (Identifier #): NCT02624986
Title: BH29812, A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B-Cell Lymphoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Details (Identifier #): NCT02194738
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Details (Identifier #): NCT02193282
Title: A081105, Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Brain
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Details (Identifier #): NCT02152982
Title: Alliance A071102, A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02869789
Title: BMS CA209-817, A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lash MD, Bradley
Sponsor: Celldex
Details (Identifier #): NCT01997333
Title: CDX011-04, A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: G1Therapeutics
Details (Identifier #): NCT02514447
Title: Protocol G1T28-03, "Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy"
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: G1Therapeutics
Details (Identifier #): NCT02499770
Title: G1T28-02; Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Details (Identifier #): NCT02339571
Title: EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Details (Identifier #): NCT02224781
Title: EA6134, A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Details (Identifier #): NCT02595944
Title: EA5142, Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Details (Identifier #): NCT02201992
Title: E4512, A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Details (Identifier #): NCT02115282
Title: E2112, A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Guthrie Patient: February 2017
Was very professional & to the point.
Guthrie Patient: February 2017
dr lash is amazing
Guthrie Patient: February 2017
We have the utmost confidence in the care that Dr. Lash is giving us!!
Guthrie Patient: February 2017
Excellent doctor, always shows concern, explains everything in easy to understand terms. Guthrie should be happy to have a doctor of this caliber on their team.
Guthrie Patient: January 2017
good
Guthrie Patient: January 2017
Dr. Lash is my Oncologist. I am a retired RN who worked in a different facility. He is wonderful. Informed and Up to Date. A tremendous asset to The Guthrie Clinic.
Guthrie Patient: January 2017
Dr Lash is a very good oncologist. He is aware that every six months is a time of anxiety. As soon he walks into the room he shares the testing results. We appreciate this.
Guthrie Patient: December 2016
Good Dr. and shot from the hip on condition.Very up to date on his treatments for me.
Guthrie Patient: December 2016
I have a high degree of confidence in and respect for Dr. Lash, he is extremely knowledgeable in his field and he also clearly demonstrates that he reviews my specific case in detail prior to our appointments. (*Name removed*)
Guthrie Patient: November 2016
I'm so pleased with Dr. Lash and his care. He has the perfect demeanor for cancer care. I like his confidence in treating my cancer. A few times I've had a question which I have submitted through the patient portal, and Robin, his nurse has responded very promptly with detailed and courteous information.